Figure 4 | Scientific Reports

Figure 4

From: Topotecan is a potent inhibitor of SUMOylation in glioblastoma multiforme and alters both cellular replication and metabolic programming

Figure 4

Topotecan alters CDK6 levels in GBM lines. (A) Topotecan causes a decrease in CDK6 protein levels in GBM lines U251, LN229, and Mz18 at concentrations of 1 μM and 10 μM. (B) The addition of MG132, a specific inhibitor of the protease activity of the 26S complex, attenuates the decrease in CDK6 protein levels previously seen in lines U251 and LN229. Representative immunoblots are shown. The band corresponding to CDK6 (40 kDa) was cropped in each lane and the total intensities were measured. Densities were normalized to corresponding actin levels and expressed as a fold difference relative to the control (DMSO). Data are means (±SD) from n = 5 independent experiments. **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 vs. DMSO. (C) Lysates from U251 cells treated either with DMSO or topotecan at 1 μM for 12hr were immunoprecipitated using an anti-CDK6 antibody followed by immunoblotting using an anti-SUMO-1 antibody. Arrow highlights the predicted CDK6-SUMO-1 band.

Back to article page